India's Glenmark to study potential COVID-19 drug combination

FILE PHOTO: Tablets of Avigan (generic name : Favipiravir), a drug approved as an anti-influenza drug in Japan and developed by drug maker Toyama Chemical Co, a subsidiary of Fujifilm Holdings Co. are displayed during a photo opportunity at Fujifilm's headquarters in Tokyo October 22, 2014. Japan's Fujifilm Holdings Corp said on Monday it was expanding the production of its Avigan anti-influenza drug to reach an additional number of Ebola patients. France and Guinea plan to conduct clinical trials of Avigan 200 mg tablets, made by Fujifilm group company Toyama Chemical Co, in Guinea to treat Ebola in mid-November, Fujifilm said in a statement. REUTERS/Issei Kato

BENGALURU (Reuters) - Glenmark Pharmaceuticals Ltd said on Tuesday it would begin a clinical trial in India to test a combination of two anti-viral drugs, favipiravir and umifenovir, as a potential COVID-19 treatment.

Glenmark has secured Indian regulatory approval for the study, which will aim to enroll 158 hospitalized patients with moderate COVID-19, the company said.